S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NYSE:EBS

Emergent BioSolutions (EBS) Stock Price, News & Analysis

$2.60
+0.16 (+6.57%)
(As of 03/27/2024 ET)
Today's Range
$2.47
$2.64
50-Day Range
$1.49
$3.41
52-Week Range
$1.42
$13.67
Volume
1.06 million shs
Average Volume
3.16 million shs
Market Capitalization
$135.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Emergent BioSolutions MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
92.7% Upside
$5.00 Price Target
Short Interest
Healthy
9.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
0.40mentions of Emergent BioSolutions in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($13.98) to ($0.25) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.55 out of 5 stars

Medical Sector

99th out of 939 stocks

Pharmaceutical Preparations Industry

38th out of 422 stocks

EBS stock logo

About Emergent BioSolutions Stock (NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Stock Price History

EBS Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Emergent BioSolutions Shares Drop on S&P Downgrade
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Q4 2023 Emergent BioSolutions Inc Earnings Call
Emergent BioSolutions: Q4 Earnings Insights
Emergent BioSolutions's Earnings: A Preview
Biotech with Baltimore facility taps new CEO
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Emergent names Joseph Papa as new CEO
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
CUSIP
29089Q10
Employees
1,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+93.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-760,500,000.00
Pretax Margin
-69.68%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$0.90 per share
Book Value
$12.51 per share

Miscellaneous

Free Float
46,408,000
Market Cap
$135.20 million
Optionable
Optionable
Beta
1.22
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Richard S. Lindahl M.B.A.Mr. Richard S. Lindahl M.B.A. (Age 60)
    Executive VP, CFO & Treasurer
    Comp: $799.38k
  • Ms. Jennifer L. Fox
    Executive VP of External Affairs, General Counsel & Corporate Secretary
  • Mr. Joseph C. Papa Jr. (Age 68)
    CEO & President
  • Mr. Robert G. Burrows
    Vice President of Investor Relations
  • Ms. Coleen Glessner
    Executive Vice President of Global Quality and Ethics & Compliance
  • Michelle Pepin
    Senior VP & Chief Human Resource Officer
  • Ms. Stephanie Duatschek
    Senior VP, Chief Strategy & Transformation Officer
  • Dr. Kelly Lyn Warfield
    Senior VP of Science & Development
  • Mr. Paul A. Williams
    Senior Vice President of Products Business
  • William Hartzel
    Senior Vice President of Manufacturing & Bioservices

EBS Stock Analysis - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price target for 2024?

2 brokerages have issued 12 month target prices for Emergent BioSolutions' shares. Their EBS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 92.7% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2024?

Emergent BioSolutions' stock was trading at $2.40 on January 1st, 2024. Since then, EBS stock has increased by 8.1% and is now trading at $2.5950.
View the best growth stocks for 2024 here
.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 4,910,000 shares, a decrease of 20.8% from the February 29th total of 6,200,000 shares. Based on an average daily volume of 3,000,000 shares, the short-interest ratio is presently 1.6 days. Currently, 9.8% of the shares of the stock are sold short.
View Emergent BioSolutions' Short Interest
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.44. The biopharmaceutical company earned $276.60 million during the quarter, compared to the consensus estimate of $247.63 million. Emergent BioSolutions had a negative net margin of 72.11% and a negative trailing twelve-month return on equity of 37.35%. During the same period in the previous year, the company posted ($0.31) earnings per share.

What ETF holds Emergent BioSolutions' stock?

Amplify Treatments, Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.73%), Vanguard Group Inc. (5.73%), Charles Schwab Investment Management Inc. (5.54%), Hotchkis & Wiley Capital Management LLC (3.18%), Assenagon Asset Management S.A. (1.61%) and Goldman Sachs Group Inc. (1.45%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EBS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners